Preeclampsia - will orphan drug status facilitate innovative biological therapies?
about
Biomarker development for presymptomatic molecular diagnosis of preeclampsia: feasible, useful or even unnecessary?Neutrophil migration into the placenta: Good, bad or deadly?Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function.Predicting the Risk to Develop Preeclampsia in the First Trimester Combining Promoter Variant -98A/C of LGALS13 (Placental Protein 13), Black Ethnicity, Previous Preeclampsia, Obesity, and Maternal Age.Evaluation of 5-HT7 receptor expression in the placentae of normal and pre-eclamptic women.Excessive Neutrophil Activity in Gestational Diabetes Mellitus: Could It Contribute to the Development of Preeclampsia?
P2860
Preeclampsia - will orphan drug status facilitate innovative biological therapies?
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Preeclampsia - will orphan drug status facilitate innovative biological therapies?
@ast
Preeclampsia - will orphan drug status facilitate innovative biological therapies?
@en
type
label
Preeclampsia - will orphan drug status facilitate innovative biological therapies?
@ast
Preeclampsia - will orphan drug status facilitate innovative biological therapies?
@en
prefLabel
Preeclampsia - will orphan drug status facilitate innovative biological therapies?
@ast
Preeclampsia - will orphan drug status facilitate innovative biological therapies?
@en
P2860
P356
P1433
P1476
Preeclampsia - will orphan drug status facilitate innovative biological therapies?
@en
P2093
Sinuhe Hahn
P2860
P356
10.3389/FSURG.2015.00007
P577
2015-02-26T00:00:00Z